victoza semaglutide vs. Ozempic: Choosing the Right GLP-1 Agonist for You Victoza® Prescription Online for Weight

Diabetes Care 36:29452951 Fonseca VA, Alvarado-Ruiz R, Raccah D et al (2012) Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Real-world data from compounding pharmacies serving male patients confirms trial findings, with average weight loss plateaus occurring between weeks 12-20 after reaching therapeutic dose

BMI 30+ or BMI 27+ with comorbidities, weight-management documentation, step therapy when applicable

Ideal Candidates for Semaglutide Semaglutide is an excellent choice for individuals seeking a non-surgical approach to significant weight loss

Future research will explore novel pathways and expand therapeutic applications